Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,192 INR | +0.37% |
|
+2.44% | +73.23% |
07-11 | Zydus Lifesciences Gets US FDA's Tentative Approval for Generic Multiple Sclerosis Drug | MT |
07-11 | Zydus Lifesciences Gets US FDA's Final Nod for Sacubitril, Valsartan Tablets | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.23% | 14.3B | |
+25.83% | 45.54B | |
+34.52% | 24.51B | |
+26.79% | 16.48B | |
+21.48% | 14.66B | |
-0.05% | 6.79B | |
-11.84% | 6.73B | |
+18.15% | 5.87B | |
-8.87% | 5.73B | |
+11.37% | 4.96B |
- Stock Market
- Equities
- ZYDUSLIFE Stock
- News Zydus Lifesciences Limited
- Zydus Lifesciences Gets US FDA's Tentative Approval for Generic Multiple Sclerosis Drug